Panel backs GSK severe asthma drug in adults, not adolescents
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline won the full support of an FDA advisory panel on 11 June for the company's severe asthma drug mepolizumab as an add-on maintenance treatment in patients with eosinophilic inflammation.
You may also be interested in...
Teva Gets EU Green Light For Reslizumab
Teva is set to get its severe asthma treatment Cinqaero onto the EU market following a positive opinion from the CHMP but, as in the US, its label will restrict its use to adult patients.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.